GSK’s Sotrovimab Floors Omicron—Antibody Cocktail Shines in Lab Tests
GlaxoSmithKline (GSK) teamed up with US partner Vir to push forward an antibody‑based COVID‑19 therapy, and guess what? The lab work on Thursday, December 2, suggests the drug is a hit against the latest Omicron variant.
The British pharma giant ran a series of snap‑trials and even hamster studies that prove the sotrovimab cocktail works against viruses engineered with key Omicron mutations. In plain language, this means the antibody mix is showing real‑world strength against the virus’s new tricks.
What’s Next?
- GSK is still vetting the results to cover every subtle mutation of Omicron.
- Compiling the final data, plus a year‑end update, is in the pipeline.
Regulatory Green Light
Meanwhile, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) tossed a stamp of approval for sotrovimab, marketed as Xevudy. If you’re at higher risk of severe COVID‑19, this drug can be your early‑bird pass—best taken within five days of symptom onset.
Summing up, GSK’s work demonstrates that this antibody cocktail isn’t just science fiction; it’s a “superhero” ready to fight the wily Omicron in real time.
